Samuel Dychter

School	Vc-academic Affairs
Address	9500 Gilman Drive # La Jolla CA 92093
vCard	Download vCard

Bibliographic

Publications

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.

Altmetrics Details

PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.

Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine. N Engl J Med. 2022 05 19; 386(20):1910-1921. Moreira ED, Kitchin N, Xu X, Dychter SS, Lockhart S, Gurtman A, Perez JL, Zerbini C, Dever ME, Jennings TW, Brandon DM, Cannon KD, Koren MJ, Denham DS, Berhe M, Fitz-Patrick D, Hammitt LL, Klein NP, Nell H, Keep G, Wang X, Koury K, Swanson KA, Cooper D, Lu C, Türeci Ö, Lagkadinou E, Tresnan DB, Dormitzer PR, Sahin U, Gruber WC, Jansen KU, C4591031 Clinical Trial Group. PMID: 35320659; PMCID: PMC9006787.

View in: PubMed Mentions: 131 Fields:
Med Medicine (General)
Translation:Humans Cells PHPublic Health CTClinical Trials
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine. 2022 03 01; 40(10):1483-1492. Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, Liau K, Lagkadinou E, Türeci Ö, Sahin U, Xu X, Koury K, Dychter SS, Lu C, Gentile TC, Gruber WC. PMID: 35131133; PMCID: PMC8702495.

View in: PubMed Mentions: 18 Fields:
All Allergy and Immunology
Translation:Humans Cells PHPublic Health CTClinical Trials
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 2021 07; 22(7):1034-1046. Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ. PMID: 34143970.

View in: PubMed Mentions: 104 Fields:
Neo Neoplasms
Translation:Humans CTClinical Trials
A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer. J Ovarian Res. 2020 Aug 31; 13(1):101. Beachler DC, Lamy FX, Russo L, Taylor DH, Dinh J, Yin R, Jamal-Allial A, Dychter S, Lanes S, Verpillat P. PMID: 32867806; PMCID: PMC7461260.

View in: PubMed Mentions: 4 Fields:
Gyn Gynecology Rep Reproductive Medicine
Translation:Humans
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Hyaluronidase PH20 Administered Intravenously in Healthy Volunteers. Curr Ther Res Clin Exp. 2020; 93:100604. Printz MA, Dychter SS, DeNoia EP, Harrigan R, Sugarman BJ, Zepeda M, Souratha J, Kang DW, Maneval DC. PMID: 32963641; PMCID: PMC7490523.

View in: PubMed Mentions: 6 Fields:
Pha Pharmacology
Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design. Future Oncol. 2018 Sep; 14(21):2103-2113. Pujade-Lauraine E, Fujiwara K, Dychter SS, Devgan G, Monk BJ. PMID: 29584456.

View in: PubMed Mentions: 34 Fields:
Neo Neoplasms
Translation:Humans CTClinical Trials
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018 01; 118(2):e3. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK. PMID: 29361630; PMCID: PMC5785755.

View in: PubMed Mentions: 5 Fields:
Neo Neoplasms
Phase 1 trials of PEGylated recombinant human hyaluronidase PH20 in patients with advanced solid tumours. Br J Cancer. 2018 01; 118(2):153-161. Infante JR, Korn RL, Rosen LS, LoRusso P, Dychter SS, Zhu J, Maneval DC, Jiang P, Shepard HM, Frost G, Von Hoff DD, Borad MJ, Ramanathan RK. PMID: 28949957; PMCID: PMC5785735.

View in: PubMed Mentions: 29 Fields:
Neo Neoplasms
Translation:Humans CTClinical Trials
Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer. Clin Cancer Res. 2016 06 15; 22(12):2848-54. Hingorani SR, Harris WP, Beck JT, Berdov BA, Wagner SA, Pshevlotsky EM, Tjulandin SA, Gladkov OA, Holcombe RF, Korn R, Raghunand N, Dychter S, Jiang P, Shepard HM, Devoe CE. PMID: 26813359; PMCID: PMC7787348.

View in: PubMed Mentions: 144 Fields:
Neo Neoplasms
Translation:Humans CTClinical Trials
Erratum to: Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. AAPS J. 2015 Nov; 17(6):1523-4. Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB. PMID: 26340861; PMCID: PMC4627462.

View in: PubMed Mentions: 1 Fields:
Dru Drug Therapy Pha Pharmacology
Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration. AAPS J. 2015 Sep; 17(5):1144-56. Rosengren S, Dychter SS, Printz MA, Huang L, Schiff RI, Schwarz HP, McVey JK, Drake FH, Maneval DC, Kennard DA, Frost GI, Sugarman BJ, Muchmore DB. PMID: 25967925; PMCID: PMC4540732.

View in: PubMed Mentions: 17 Fields:
Dru Drug Therapy Pha Pharmacology
Translation:Humans
Tolerability and pharmacokinetic properties of ondansetron administered subcutaneously with recombinant human hyaluronidase in minipigs and healthy volunteers. Clin Ther. 2014 Feb 01; 36(2):211-24. Dychter SS, Harrigan R, Bahn JD, Printz MA, Sugarman BJ, DeNoia E, Haughey DB, Fellows D, Maneval DC. PMID: 24486335.

View in: PubMed Mentions: 8 Fields:
Dru Drug Therapy The Therapeutics
Translation:Humans Animals CTClinical Trials
Subcutaneous drug delivery: a route to increased safety, patient satisfaction, and reduced costs. J Infus Nurs. 2012 May-Jun; 35(3):154-60. Dychter SS, Gold DA, Haller MF. PMID: 22498485.

View in: PubMed Mentions: 14 Fields:
Nur Nursing
Translation:Humans
Intravenous therapy: a review of complications and economic considerations of peripheral access. J Infus Nurs. 2012 Mar-Apr; 35(2):84-91. Dychter SS, Gold DA, Carson D, Haller M. PMID: 22382792.

View in: PubMed Mentions: 40 Fields:
Nur Nursing
Translation:Humans
Comparison of the tolerability of recombinant human hyaluronidase + normal saline and recombinant human hyaluronidase + lactated ringer's solution administered subcutaneously: A phase IV, double-blind, randomized pilot study in healthy volunteers. Curr Ther Res Clin Exp. 2009 Dec; 70(6):421-38. Dychter SS, Ebel D, Mead TR, Yocum RC. PMID: 24692835; PMCID: PMC3969977.

View in: PubMed Mentions: 5 Fields:
Pha Pharmacology
Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006 Nov 07; 145(9):660-4. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, Morgan JA, Dychter SS, Larsen PR, Demetri GD, Alexander EK. PMID: 17088579.

View in: PubMed Mentions: 94 Fields:
Int Internal Medicine
Translation:Humans CTClinical Trials